Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer

European Respiratory Journal

Volumn 14, Issue 6, 1999, Pages 1376-1380

  Bury, Th ^a   Corhay, J L ^b   Duysinx, B ^b   Daenen, F ^b   Ghaye, B ^b   Barthelemy, N ^b   Rigo, P ^b   Bartsch, P ^b  

^a CHU SART TILMAN   (Belgium)

^b NONE

Author keywords

Positron emission tomography; Post treatment change; Recurrent lung cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOISOTOPE DISTRIBUTION;

EID: 0033391270     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.99.14613769     Document Type: Article

References (16)

1. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314.
2. Rege S, Hoh C, Glaspy J, et al. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose. Cancer 1993; 72: 82-90.
3. Nolop K, Rhodes C, Brudin L, et al. Glucose utilization in vivo by human pulmonary neoplasms. Cancer 1987; 60: 2682-2689.
4. Bury T, Dowlati A, Paulus P, et al. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur Respir J 1996; 9: 410-414.
5. Bury T, Paulus P, Dowlati A, et al. Staging of the mediastinum: value of PET imaging in non-small cell lung cancer. Eur Resp J 1996; 9: 2560-2564.
6. Bury T, Dowlati A, Paulus P, et al. Whole-body 18FDG positron emission tomography in the staging of lung cancer. Eur Resp J 1997; 10: 2529-2534.
7. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710-1717.
8. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas 1960; 20: 37-46.
9. Glazer H, Lee J, Levitt R, et al. Radiation fibrosis: differentiation from recurrent tumor by MR imaging. Radiology 1985; 156: 721-726.
10. Glazer H, Aronberg D, Sagel S, Emami B. Utility of CT in detecting postpneumectomy carcinoma recurrence. Am J Roentgenol 1984; 142: 487-494.
11. Bourgouin P, Cousineau G, Lemire P, Delvecchio P, Hebert G. Differentiation of radiation-induced fibrosis from recurrent pulmonary neoplasm by CT. J Can Assoc Radiol 1987; 38: 23-26.
12. Pauwels E, McCready R, Stoot J, Van Deurzen D. The mechanisms of accumulation of tumour-localising radiopharmaceuticals. Eur J Nucl Med 1998; 25: 277-305.
13. Patz E, Lowe V, Hoffman J, Paine S, Harris L, Goodman P. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-Deoxy-D-glucose. Radiology 1994; 191: 379-382.
14. Inoue T, Kim E, Komaki R, et al. Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 1995; 36: 788-793.
15. Frank A, Lefkowitz D, Jaeger S, et al. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings. Int J Radiation Oncology Biol Phys 1995; 32: 1495-1512.
16. Kubota K, Yamada S, Ishiwaka K, et al. Evaluation of the treatment response of lung cancer with positron emission tomography and L-[methyl-11C] methionine: a preliminary study. Eur J Nucl Med 1993; 20: 495-501.